Patient enrollment in AVP-923 PRIME Study completed
Posted: Tue Jul 02, 2013 1:21 am
Avanir Pharmaceuticals, Inc. announced completion of patient enrollment in the company's phase II, placebo controlled study testing three doses of AVP-923 for the treatment of central neuropathic pain in multiple sclerosis. Top-line results from this study are expected in the fourth calendar quarter of 2013.
"Final completion of enrollment in PRIME is an important milestone in the AVP-923 development pathway," said Joao Siffert, MD, chief scientific officer at Avanir. "We are looking forward to the results from this study to help guide design of our phase III studies in neuropathic pain......." - Read More - http://www.ms-uk.org/index.cfm/emergingtherapies
"Final completion of enrollment in PRIME is an important milestone in the AVP-923 development pathway," said Joao Siffert, MD, chief scientific officer at Avanir. "We are looking forward to the results from this study to help guide design of our phase III studies in neuropathic pain......." - Read More - http://www.ms-uk.org/index.cfm/emergingtherapies